| Medical and Health Sciences | Lifetime | 134 | GB 16 | 99.99 |
| Rheumatology | Lifetime | 4 | GB 1 | 99.98 |
| Hematology | Lifetime | 127 | GB 5 | 99.21 |
| Pathology and Forensic Medicine | Lifetime | 352 | GB 31 | 98.63 |
| Immunology | Lifetime | 449 | GB 33 | 98.77 |
| Medical Genetics | Lifetime | 202 | GB 14 | 98.51 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 578 | GB 50 | 98.51 |
| Clinical Pharmacology | Lifetime | 937 | GB 90 | 95.52 |
| Orthopedics and Sports Medicine | Lifetime | 736 | GB 69 | 91.15 |
| Rheumatology | 2021-2025 | 40 | GB 6 | 99.27 |
| Pathology and Forensic Medicine | 2021-2025 | 472 | GB 29 | 78.77 |
| Immunology | 2021-2025 | 749 | GB 42 | 75.62 |
| Systemic Lupus Erythematosus Research | Lifetime | 1 | GB 1 | 99.97 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 2 | GB 1 | 99.98 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 2 | GB 1 | 99.97 |
| Biosimilars and Bioanalytical Methods | Lifetime | 2 | GB 1 | 99.84 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 27 | GB 1 | 99.87 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 47 | GB 3 | 99.86 |
| Musculoskeletal synovial abnormalities and treatments | Lifetime | 8 | GB 2 | 99.73 |
| Spondyloarthritis Studies and Treatments | Lifetime | 11 | GB 3 | 99.80 |
| Lymphoma Diagnosis and Treatment | Lifetime | 60 | GB 4 | 99.76 |
| Bone and Joint Diseases | Lifetime | 99 | GB 12 | 99.07 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 124 | GB 14 | 98.79 |
| Inflammatory mediators and NSAID effects | Lifetime | 261 | GB 29 | 98.27 |
| Systemic Sclerosis and Related Diseases | Lifetime | 266 | GB 25 | 97.82 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 396 | GB 28 | 97.84 |
| Toxin Mechanisms and Immunotoxins | Lifetime | 293 | GB 15 | 97.18 |
| Osteoarthritis Treatment and Mechanisms | Lifetime | 494 | GB 43 | 97.77 |
| Viral Infections and Immunology Research | Lifetime | 735 | GB 64 | 96.59 |
| Musculoskeletal Disorders and Rehabilitation | Lifetime | 150 | GB 23 | 95.03 |
| Peripheral Neuropathies and Disorders | Lifetime | 442 | GB 38 | 96.64 |
| Inflammasome and immune disorders | Lifetime | 737 | GB 39 | 94.15 |
| Sarcoidosis and Beryllium Toxicity Research | Lifetime | 679 | GB 51 | 92.23 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 24 | GB 5 | 99.31 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 36 | GB 8 | 98.72 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 61 | GB 6 | 98.68 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 432 | GB 29 | 95.65 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 490 | GB 28 | 93.05 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 251 | GB 16 | 88.54 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 336 | GB 26 | 90.45 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 613 | GB 35 | 85.74 |
| Peripheral Neuropathies and Disorders | 2021-2025 | 639 | GB 40 | 85.01 |
| Sarcoidosis and Beryllium Toxicity Research | 2021-2025 | 436 | GB 39 | 82.20 |
| Musculoskeletal synovial abnormalities and treatments | 2021-2025 | 361 | GB 25 | 73.02 |
| Musculoskeletal Disorders and Rehabilitation | 2021-2025 | 853 | GB 113 | 42.46 |
